

Communications Handbook for Clinical Trials

**Strategies, tips, and tools
to manage controversy,
convey your message, and
disseminate results**

By
Elizabeth T. Robinson
Deborah Baron
Lori L. Heise
Jill Moffett
Sarah V. Harlan

Preface by
Archbishop Desmond M. Tutu



Communications Handbook for Clinical Trials

**Strategies, tips, and tools
to manage controversy,
convey your message, and
disseminate results**

By
Elizabeth T. Robinson
Deborah Baron
Lori L. Heise
Jill Moffett
Sarah V. Harlan

Preface by
Archbishop Desmond M. Tutu



Communications Handbook for Clinical Trials: Strategies, Tips, and Tools to Manage Controversy, Convey Your Message, and Disseminate Results

Authors: Elizabeth T. Robinson, Deborah Baron, Lori L. Heise, Jill Moffett, Sarah V. Harlan

**© Family Health International
ISBN: 1-933702-57-5**

The handbook is co-published by the Microbicides Media and Communications Initiative, a multi-partner collaboration housed at the Global Campaign for Microbicides at PATH in Washington, DC, and by Family Health International in Research Triangle Park, NC, USA.

**Global Campaign for Microbicides
PATH
1800 K Street NW, Suite 800
Washington, DC 20006 USA
Tel: +1.202.822.0033
Web: www.mmci-communications.org
www.global-campaign.org**

**Family Health International
P.O. Box 13950
Research Triangle Park, NC 27709 USA
Tel: +1.919.544.7040
E-mail: publications@fhi.org
Web: www.fhi.org**

This work was made possible by the generous support of the American people through the U.S. Agency for International Development (USAID) through dual grants to the Microbicides Media and Communications Initiative (MMCI), a project of the Global Campaign for Microbicides at PATH, and to Family Health International (FHI). The contents are the responsibility of FHI and do not necessarily reflect the views of USAID or the United States Government. Financial assistance was provided to FHI by USAID under the terms of Cooperative Agreement GPO-A-00-05-00022-00, the Contraceptive and Reproductive Health Technologies Research and Utilization (CRTU) Program, and Cooperative Agreement GHO-A-00-09-00016-00, the Preventive Technologies Agreement (PTA) Program, and to PATH by USAID under the terms of Cooperative Agreement GPH-A-00-01-00005-00, the HealthTech IV Program.

**To request additional copies of the handbook, e-mail:
handbook@mmci-communications.org.**

Contents

Preface	vii
Acknowledgments	x
Chapter One: About This Handbook	1
I. The purpose of this handbook	2
II. Challenges posed by clinical trials	4
III. Origins of the handbook	5
IV. How this handbook is organized	5
Chapter Two: Preparing and Budgeting for Communications	9
I. Doing your homework—a “desk review”	9
II. Conducting an environmental scan	10
III. Developing a communications budget	17
IV. Assembling a communications team	21
V. Training staff and spokespersons	22
Chapter Three: Developing a Strategic Communications Plan	27
I. Background and environmental analysis	27
II. Goals and objectives	29
III. The communications team	29
IV. Identification of key stakeholders	31
V. Strategy for ongoing communication with stakeholders	36
VI. Strategy for managing controversy—crisis communications	38
VII. Dissemination plan for trial results	39
VIII. Materials to support the trial	39
IX. Monitoring and evaluation	42
Chapter Four: Communications During the Trial	45
I. Announcing the start of your trial	45
II. Maintaining good communications	50
III. Tracking and responding to emerging issues	62
IV. Preparing for interim analyses	65
V. Disseminating results	67
Chapter Five: Preventing and Managing a Crisis	69
I. What is a crisis communications plan?	70
II. Why is a crisis communications plan needed?	70
III. Preventing crises	72
IV. Preparing for potential controversy	75
V. Developing a rapid response procedure	78

VI.	Implementing your crisis communications plan	80
VII.	Managing unexpected trial closures	81
	Chapter Six: Preparing for and Disseminating Study Results	87
I.	The minimum package of dissemination activities	88
II.	The dissemination team and plan: compiling the core elements	88
III.	Timing, timelines, and time zones	94
IV.	Planning for various outcome scenarios	100
V.	Managing embargoes and pre-release issues	104
VI.	Orchestrating the public announcement	107
VII.	Post-announcement dissemination activities	112
	Chapter Seven: Developing and Using Key Messages	115
I.	Why key messages are important	116
II.	How to develop key messages and supporting messages	117
III.	Creating tailored messages for any situation	123
IV.	Refining and testing your messages	125
V.	Delivering key messages	126
	Chapter Eight: Communicating Science Clearly	131
I.	Why research is necessary	131
II.	Translating the language of clinical trials	137
III.	Demystifying statistics	143
IV.	Five ways to avoid misunderstandings	146
	Chapter Nine: Working with the Media	149
I.	Understanding the media	149
II.	Developing a media strategy	156
III.	Responding to media requests	166
IV.	Getting your message across	170
V.	Being interviewed by the media	172
VI.	Helping journalists write good stories	175
VII.	Nurturing relationships with the media	177
	Appendices	
	Appendix 2.1 A Risk Assessment Tool	180
	Appendix 2.2 Microbicide Trials Network: Communications Planning Survey	182
	Appendix 2.3 “Thirty Tough Questions” for Trial Staff	190
	Appendix 3.1 Sample Strategic Communications Plan	192
	Appendix 3.2 “Getting to Know Your Stakeholders” Template	195
	Appendix 3.3 Contact List Template	196
	Appendix 3.4 Samples of Newsletters for Clinical Trials	197
	Appendix 3.5 Sample of Study “Backgrounder”	200
	Appendix 3.6 Sample External Questions and Answers (Q&A)	202
	Appendix 4.1 Template for a Monthly Summary Report on Communications	205
	Appendix 5.1 How Unexpected Closures Can Affect Other Trial Sites: The Cellulose Sulfate Trial Closure in South Africa	207

Appendix 5.2 Illustrative Crisis Communications Plan	208
Appendix 6.1 Sample of a Results Dissemination Plan by a South African Site	211
Appendix 6.2 Sample of a Results Dissemination Plan by a Peruvian Site	214
Appendix 6.3 Case Study: Timelines and Tasks for Disseminating the Results of HPTN 035	217
Appendix 6.4 Sample Questions to Include in an Internal Q&A for Trial Results, Based on Three Outcome Scenarios	220
Appendix 6.5 Sample Letter to Ethics Committee Requesting Review of Materials Needed for Dissemination	222
Appendix 6.6 Sample Letter Inviting Community Stakeholders to Learn Study Results	223
Appendix 7.1 Sample Brochure to Share Study Results with a Community	224
Appendix 7.2 Sample Brochure to Share Study Results with a Ministry of Health	225
Appendix 7.3 Sample Key Messages Grid	226
Appendix 7.4 Alternative Sample Grid to Create Compelling Messages	227
Appendix 9.1 Managing Media Inquiries: Worksheet for Media Calls	230
Appendix 9.2 Sample Standard Operating Procedures (SOPs) for Media Inquiries	231
Appendix 9.3 Sample Letter to the Editor in Response to a Negative News Article	235
Appendix 9.4 Author Data Form for Writing a Press Release	236
Appendix 9.5 Press Release Template	237
Appendix 9.6 Sample Press Release	239
Selected Additional Resources	241
Acronyms	247
References	249
List of Boxes and Figures	
Box 1.1. Clinical trial milestones and parallel communications tasks	7
Box 2.1. Questions for conducting an internal environmental scan	11
Box 2.2. Formative research: Impacta Peru’s strategy	15
Box 2.3. Learn from other trials when planning your own	16
Box 2.4. Budget template for a basic communications program	18
Box 2.5. Budget template for an expanded communications program	19
Box 2.6. Answering tough questions: practice does make a difference	23
Box 3.1. Sample communications team template, organized by communications function	30
Figure 3.1. Audience segmentation by external and internal groups	33
Box 3.2. Communicating with key stakeholders	34
Box 3.3. Sample “getting to know your stakeholders” template	35
Box 3.4. Sample contact list entries	36
Figure 3.2. Key milestones of a rotavirus vaccine trial	38
Box 3.5. Sample list of materials and tools to support the communications plan	41
Box 3.6. Respecting cultural sensitivities about wording	42
Box 3.7. Monitoring communications and media for a study	43
Box 4.1. Sample spreadsheet for trial launch announcements	48

Box 4.2. Advantages and disadvantages of drawing attention to a study launch: "First South African-developed HIV vaccines begin testing in SA"	49
Box 4.3. Implementing our plan: ongoing communication at multiple levels is key	51
Box 4.4. Internal communications within the Male Circumcision Consortium: monthly updates	53
Box 4.5. Lessons learned regarding ethical clearance for communications efforts	55
Box 4.6. Suggested steps for review and approval of educational materials	57
Box 4.7. Monitoring community voices through participants: CAPRISA 004	64
Box 4.8. Sample e-mail alerting stakeholders to upcoming DSMB meeting	66
Box 5.1. The value of having a systematic way to reach out quickly to site teams	71
Box 5.2. Overarching principles for crisis communications	73
Box 5.3. Sample procedure for rapid response to crises	79
Box 5.4. The Malaria Vaccine Initiative's crisis communications card	80
Box 5.5. What to do if safety concerns lead to an unexpected trial closure	82
Box 5.6. Lessons learned from the cellulose sulfate trial about emergency trial closures	84
Box 6.1. Template for researchers: how to plan for research dissemination	90
Box 6.2. Face-to-face meetings at community level were most effective	92
Box 6.3. Review, reflect, revise: updating contact lists, messages, and materials	93
Box 6.4. Advice on updating communications products	95
Box 6.5. Choosing a meeting for the presentation of results	96
Box 6.6. Timing the announcement of results: the AIDS vaccine study in Thailand	98
Box 6.7. Communications timeline and milestones for dissemination of trial results	99
Box 6.8. Scenario planning: an investment in capacity building	101
Box 6.9. What is the U.S. Securities and Exchange Commission and how could it affect the timing of the release of trial results?	106
Box 6.10. Giving voice to trial participants	108
Box 6.11. Organizing different meetings for different groups of local stakeholders	109
Box 6.12. Disseminating information, demanding information: the dual roles of advocates when trials close	110
Box 6.13. Dissemination factors that promote the use of research results	112
Box 7.1. Sample messages adapted for patients and providers	121
Figure 7.1. Sample grid of key messages	122
Figure 7.2. Sample grid to outline introductory and key messages	123
Box 7.2. Five things to remember when delivering key messages	127
Figure 7.3. VOICE study: explaining drug resistance	128
Figure 7.4. GCM training slide on drug resistance	129
Figure 8.1. Explaining the process of drug discovery to a scientifically literate audience	134
Figure 8.2. Overview of the drug development process	135
Figure 8.3. Logic of drug development	135
Figure 8.4. Microbicide, vaccine, and drug development	136
Figure 8.5. Research pipeline in 2007	136
Box 8.1. Replacing jargon with everyday words	138

Box 8.2. Everyday words that can mislead	139
Box 8.3. Baobab trees used to explain serodiscordance	140
Figure 8.6. Experience of a Phase III participant	140
Box 8.4. Using props to explain clinical trial concepts	141
Box 8.5. The importance of field-testing materials: lessons learned from Orange Farm	142
Box 8.6. Present scientific results in simple, clear terms	145
Box. 8.7. Speak in ways that emphasize the human face of trial participants	146
Box 9.1. News media goals versus trial site goals	151
Box 9.2. Have a clear message to tell us	152
Box 9.3. Giving journalists the right information at the right time	153
Box 9.4. What makes a story newsworthy?	154
Box 9.5. Beware of the media's trigger vocabulary	155
Box 9.6. Approaches for sharing information through news media	157
Box 9.7. Characteristics of different types of media	160
Box 9.8. Using grassroots media	161
Box 9.9. Sample media monitoring grid	162
Box 9.10. What every site should know about responding to Internet media	164
Box 9.11. How to set up a Google news alert	165
Box 9.12. Questions to ask journalists	167
Box 9.13. How to "Google" a reporter	168
Box 9.14. Important terminology related to news media	169
Box 9.15. Interview techniques: using the ABC approach	171
Box 9.16. How to get your message across using flagging	171
Box 9.17. Avoid being misquoted	174
Box 9.18. The importance of reacting quickly to inaccuracies in the media	176
Box 9.19. Understanding media constraints is a key to being a trusted source	178
Box 9.20. Communicating your passion for the issue	178
Box 9.21. When key spokespeople become statesmen for the field	179

Preface

One of the greatest joys and responsibilities of democracy is the freedom of speech. We have the luxury and the burden to communicate our struggles, our hopes, our work, and our passion. In the fight against HIV and the long journey to finding new ways for those most vulnerable to protect themselves, a key challenge is to communicate the logic and the promise of this important work.

Research to find new methods of HIV prevention is a complex and arduous endeavor. It involves building trust across divides of race, gender, culture, and privilege. It demands dedication on the part of scores of counselors, study nurses, lab technicians, outreach workers, and scientists. It requires commitment, honesty, and sacrifice from hundreds and even thousands of participants. And it requires communities to embrace an often foreign enterprise—that of scientific research.


Clinical research is hard to explain to people with little or no scientific background. It is like a foreign language, a different culture—but one that holds great promise for the poor and the rich alike. It is up to us to ensure that the potential benefits of science reach all people and that participants and communities understand and can engage productively as full partners in the research endeavor.

Global guidelines, such as the *Good Participatory Practice Guidelines for Biomedical HIV Prevention Trials* recently published by UNAIDS, in collaboration with AVAC: Global Advocacy for HIV Prevention, are defining new standards for equitable practice between researcher and participant, between donors and community, and between those designing and implementing research and those poised to reap its benefits. This document sets out principles and minimum standards for engaging communities in the conduct of research, including building research literacy, community engagement, and communicating with research stakeholders.

But even the greatest guidelines or constitutions in the world cannot succeed unless we have the practical tools to make them work for everyday people in their everyday lives. For the investigators, study coordinators, and community liaison officers working on the frontlines of these trials, this handbook will serve as one such tool, providing guidance for translating expectations regarding stakeholder communication into concrete practice. The Good Participatory Practice (GPP) guidelines call for a “written communication plan” as an essential element for all future trials. This handbook describes how to develop an overall communications plan, with special plans for research dissemination and crisis communication.

The HIV field is not alone in confronting changing expectations and new challenges when it comes to communicating about research. Across the board, an increasing number of actors now see themselves as stakeholders in the research process. I see this development as a positive one and an evolution we must embrace. As our world gets increasingly complex, the need for science and research literacy becomes ever more acute. This book, and others like it, is an important contribution toward bridging the worlds of science and community—of bringing more and more people into the conversation about research. Increasingly, science is touching all of our lives and we must ensure that even the most marginalized people are part of the dialogue.

God bless you.

A handwritten signature in black ink, appearing to read "Desmond M. Tutu". The signature is written in a cursive, slightly slanted style.

Archbishop Desmond M. Tutu

Acknowledgments

The *Communications Handbook for Clinical Trials* grew out of the collective experience of scores of individuals who have dedicated themselves to demystifying science and ensuring that both the process and the outcomes of clinical research are communicated clearly. From the beginning, the process of creating the handbook has been a collaborative effort, and the final product reflects the wealth of this input.

The authors would especially like to thank the members of the Microbicides Media and Communications Initiative (MMCI), an ongoing “community of practice” that meets regularly to share strategies for handling the complex communications challenges posed by the conduct of large-scale effectiveness trials of HIV prevention technologies in Africa and other resource-limited settings. Many of the stories and insights contained herein derive from the experiences of MMCI members, who have been incredibly generous in sharing their knowledge, materials, and hard-won wisdom about clinical trial communication. We particularly thank all MMCI Steering Committee members (former and current): Quarraisha Abdool Karim, Centre for the AIDS Programme of Research in South Africa (CAPRISA); Manju Chatani-Gada, AVAC: Global Advocacy for Prevention; Mitzy Gafos, Microbicides Development Programme (MDP), Africa Centre; Yasmin Halima, Global Campaign for Microbicides (GCM); Polly Harrison, AVAC; Lori Heise, London School of Hygiene and Tropical Medicine (LSHTM) (co-author); Neetha Morar, South African Medical Research Council (MRC); Oliver Mweemba, University of Zambia; Patrick Ndase, Microbicide Trials Network (MTN); Pamela Norick, International Partnership for Microbicides (IPM); Elizabeth T. Robinson, Family Health International (FHI) (co-author); Lisa Rossi, MTN; and Deborah Baron, MMCI coordinator, GCM (co-author).

A rich source of learning came from an in-person consultation that we held in March 2009, co-sponsored by the MMCI and CAPRISA. This meeting brought together 45 investigators, trial staff, and community advocates in Durban, South Africa, to solicit feedback on early drafts of the handbook and to collect examples and lessons learned from the lived experience of those working on the frontlines of communicating about HIV prevention trials in Africa. These individuals included:

Quarraisha Abdool Karim
CAPRISA
South Africa

Salim Abdool Karim
CAPRISA
South Africa

Natasha Arulappan
CAPRISA
South Africa

Nomampondo Barnabas
GCM
South Africa

Deborah Baron
MMCI/GCM
South Africa

Cheryl Baxter
CAPRISA
South Africa

Kim Best
FHI
USA

Sarah Chiduo
Kilimanjaro Christian Medical Centre
Tanzania

Anne Coletti
FHI
USA

Jo-Anne Collinge
Meropa/IPM
South Africa

Nozizwe Dladla-Qwabe MRC South Africa	Nkosinathi Mhlongo Africa Centre South Africa
Michelle Folsom PATH South Africa	Margaret Mlingo UZ-UCSF Zimbabwe
Glenda Gray Perinatal HIV Research Unit (PHRU), University of the Witwatersrand South Africa	Neetha Morar MRC South Africa
Sarah V. Harlan FHI USA	Nelly Mugo University of Nairobi University of Washington (UW)/International Clinical Research Center (ICRC) Kenya
Norma Hatcher CAPRISA South Africa	Misiwe Mzimela Africa Centre South Africa
Lori L. Heise GCM/LSHTM USA/UK	Kalendri Naidoo CAPRISA South Africa
Kenneth Kintu Makerere University-John Hopkins University (MU-JHU) Research Collaboration Uganda	Tarryn Naidoo MRC South Africa
Nadine Landsmann MRC South Africa	Vivienne Naidoo GCM South Africa
Londiwe Luthuli CAPRISA South Africa	Teopista Nakyanzi MU-JHU Research Collaboration Uganda
Silvia Maarschalk CAPRISA South Africa	Sibusiso Nhleko MRC South Africa
Leila Mansoor CAPRISA South Africa	Fanele Ntombela CAPRISA South Africa
William Mapham Reproductive Health & HIV Research Unit (RHRU), University of the Witwatersrand South Africa	Victoria Oyier International Centre for Reproductive Health (ICRH)/IPM Tanzania
Nyaradzo Mgodli University of Zimbabwe/University of California San Francisco (UZ-UCSF) Zimbabwe	Gita Ramjee MRC South Africa

Malebo Ratlhangana Setshaba Research Centre/Medical University of Southern Africa (MEDUNSA) South Africa	Morenike Ukpong New HIV Vaccine and Microbicide Advocacy Society (NHVMAS) Nigeria
Cheri Reid Centre for Infectious Disease Research in Zambia (CIDRZ) Zambia	Vulindlela trial participant (name withheld) CAPRISA South Africa
Sechele Sechele Centers for Disease Control (CDC)/BOTUSA (Botswana-USA) Botswana	Mitchell Warren AVAC USA
Junaid Seedat International AIDS Vaccine Initiative (IAVI) South Africa	Constancia Watadzaushe UZ-UCSF Zimbabwe

We are particularly grateful to the many individuals who authored case studies, shared materials, and reviewed earlier drafts of the publication. Chapters of the handbook were shared with over 80 individuals in 13 countries, and we are deeply indebted to the many individuals who provided detailed comments, research examples, and additional field experiences. This input was invaluable in making the document relevant and true to life. We would also like to thank the many individuals in Africa, Asia, Europe, North America, and South America, and who contributed their time and insights by agreeing to be interviewed by the authors. These interviews helped us to better understand the needs and experiences of the field and shaped both the content and structure of the final publication.

The individuals who contributed substantially to this handbook through time, materials, expert review, interviews, or authored contributions, include:

Quarraisha Abdool Karim CAPRISA South Africa	Jonathan Baum Consultant USA
Salim Abdool Karim CAPRISA South Africa	Ward Cates FHI USA
Silas Achar FHI Kenya	Connie Celum UW/ICRC USA
Kawango Agot Impact Research and Development Organization Kenya	Manju Chatani-Gada AVAC USA
Lisa Marie Albert FHI USA	Lee Claypool USAID USA
Nomampondo Barnabas GCM South Africa	Paul Cleary Center for Interdisciplinary Research on AIDS (CIRA) USA

Allison Clifford
PATH
USA

Anne Coletti
FHI
USA

Jo-Anne Collinge
Meropa/IPM
South Africa

Somer Cooper
FHI
USA

Amy Corneli
FHI
USA

Sinead Delany-Moretlwe
RHRU
South Africa

Gai Doran
CIRA
USA

Samukeliso Dube
GCM
South Africa

Paul Feldblum
FHI
USA

Michelle Folsom
PATH
South Africa/USA

Anna Forbes
GCM
USA

Mitzy Gafos
MDP/Africa Centre
South Africa

Theresa Gamble
FHI
USA

Pedro Goicochea
Investigaciones Medicas en Salud
Peru

Glenda Gray
PHRU, University of the Witwatersrand
South Africa

David Grimes
FHI
USA

James Hakim
UZ-UCSF
Zimbabwe

Daniel Halperin
Harvard University School of Public Health
USA

Sharon Hillier
MTN
USA

Jessica Justman
Mailman School of Public Health,
Columbia University
USA

Kenneth Kintu
MU-JHU Research Collaboration
Uganda

Stella Kirkendale
FHI
USA

Newton Kumwenda
Queen Elizabeth Central Hospital
Malawi

Annette Larkin
CONRAD
USA

Mary Latka
AURUM Institute
South Africa

Londine Rosebud Lethuli
CAPRISA
South Africa

Natasha Mack
FHI
USA

Kathleen MacQueen
FHI
USA

Bernadette Madlala
CAPRISA
South Africa

William Mapham
RHRU, University of the Witwatersrand
South Africa

Derrick Mapp
Shanti/L.I.F.E. Institute
USA

Melissa May
Population Council
USA

Jowet Mayisela
Traditional Leader
South Africa

Vivian McLaurin
FHI
USA

Nyaradzo Mgodzi
UZ-UCSF
Zimbabwe

Margaret Mlingo
UZ-UCSF
Zimbabwe

Mukelisiwe Mlotshwa
CAPRISA
South Africa

Allison Mobley
UW/ICRC
USA

Neetha Morar
MRC
South Africa

Monique Mueller
FHI
USA

Nelly Mugo
University of Nairobi and UW/ICRC
Kenya

Kennedy Mundia
MDP
Zambia

Kanya Ndaki
IRIN/Plus News Southern Africa
South Africa

Duduzile Ndouli
CAPRISA
South Africa

Kenneth Ngure
Partners in Prevention
Kenya

Pam Norick
IPM
USA

Fanelsibonge Ntombela
CAPRISA
South Africa

Gabisile Nxele
CAPRISA
South Africa

Ikoma Obunge
University of Port Harcourt Teaching Hospital
Nigeria

Lynn Paxton
CDC
USA

Leigh Peterson
FHI
USA

Deborah Phillips
PATH
USA

David Poland
MVI/PATH
USA

Eileen Quinn
PATH
USA

Bobby Ramakant
India

Gita Ramjee
MRC
South Africa

Malebo Ratlhagana
Setshaba Research Centre/MEDUNSA
South Africa

Cheri Reid
CIDRZ
Zambia

Lisa Reilly
U.S. Military HIV Research Program
USA

Janet Robinson
FHI
Thailand

Lisa Rossi MTN USA	Doug Taylor FHI USA
Seema Sahay National AIDS Research Institute (NARI) India	Brad Tytel Global Health Strategies (GHS) USA
Jorge Sanchez Asociación Civil Impacta Salud y Educacion Peru	Morenike Ukpong NHVMAS Nigeria
Sechele Sechele CDC/BOTUSA Botswana	Francois Venter RHRU, University of the Witwatersrand South Africa
Junaid Seedat IAVI South Africa	Mitchell Warren AVAC USA
Kathleen Shears FHI USA	Debra Weiner FHI USA
Nirupama Sista HIV Prevention Trials Network (HPTN) USA	Katie West Slevin GCM USA
Dirk Taljaard Progressus South Africa	Merywen Wigley FHI USA
Roger Tatoud MDP/Imperial College London UK	Christina Wong FHI USA

We extend special thanks to Sten Vermund, principal investigator of the HPTN, and Quarraisha Abdool Karim, chair of HPTN's Information and Communication Committee, for having facilitated the review of the handbook by so many HPTN research sites.

In addition, we would like to thank the following people for their support: Sarah Alexander, HIV Vaccine Trials Network (HVTN); Lillian Anomnachi, FHI-Nigeria; Mark Aurigemma, i-PrEx; Luann Tia Blount, IPM; Allison Burns, FHI; Terry Butler, CDC; Mialy Clark, GCM; Lavinia Crawford-Browne, Desmond Tutu HIV Foundation; Alex Maiolo; Carol Manion, FHI; Carrin Martin, MRC; Timothy Mastro, FHI; Tom Milroy, consultant; Vivienne Naidoo, GCM; Patsy Norman, FHI; Bindya Patel, GCM; Scott Rose, FHI; Kenneth Schulz, FHI; Holly Seltzer, IPM; Margie Shiels, FHI; Stephanie Stuart, PATH; Monica Wanjiru, Population Council.

This handbook was produced with the generous financial support of the U.S. Agency for International Development (USAID), via dual grants to MMCI, a project of the Global Campaign for Microbicides at PATH, and to Family Health International. Additional financial support for printing was provided by the International Partnership for Microbicides.

Finally, the authors offer a special thanks to Kathleen MacQueen for graciously opening her home in Chapel Hill, NC, to the writing team for a week-long writing retreat in 2009.